ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a biotechnology firm specializing in pharmaceutical preparations with a market capitalization of $1.12 billion, announced a recent change to its Board of ...

Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Attovia Therapeutics doses first participant in phase 1 study of ATTO-1310, its novel HLF anti-IL-31 ATTOBODY to treat chronic pruritus: Fremont, California Saturday, January 25, ...

Press Release ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data ...

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D tissues with unprecedented speed, uniformity, and versatility.

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in ...

Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival (“DFS”) expected in H1 2025; positive results could support rapid advancement into Phase 3 ...

The federal agency has registered the case on April 19 based on a reference from the ministry of home affairs (MHA), which ...

One year after surgery, 97% of patients in the ≥ 85 group and 100% of patients in the control group could void spontaneously.